MEA Psoriasis Drugs Market

MEA Psoriasis Drugs Market Size (2023 to 2028)

The Psoriasis Drugs Market size in the Middle East & Africa is expected to be worth USD 0.74 billion by 2028 from USD 0.52 billion in 2023, growing at a CAGR of 7.24% between 2023 and 2028.

Psoriasis can be caused by various conditions and disorders, including strep throat, cold, dry weather, wounds, scrapes, bug bites, severe sunburn, stress, smoking, and secondhand smoke, a family history of psoriasis, and high alcohol intake.

Due to a rise in psoriasis research and pipeline products and a growth in disease burden and demand for psoriasis therapies in emerging nations, the psoriasis drugs market in the MEA region is significantly growing. The expanding senior population is another primary driver promoting the psoriasis pharmaceutical industry, as the condition primarily affects the elderly. The rising incidence of psoriasis has fueled the growth of the psoriasis pharmaceuticals business by increasing the usage of various psoriatic pharmaceutical products and therapies across the Middle East and Africa.

The market growth in this region is further expected to accelerate due to an increase in psoriasis research and pipeline products and an increase in disease burden and demand for psoriasis treatments in emerging nations.

However, the market is expected to be limited by most available treatments' adverse effects and the high cost of therapy. Though drug efficacy supports market growth in treating the condition, negative market variables such as the high cost of psoriasis therapy may stifle market expansion.

This research report on the Middle East and Africa psoriasis drugs market has been segmented and sub-segmented into the following categories:

By Drug Type:

• Pharmaceuticals
• Biopharmaceuticals

By Route of Administration:

• Topical
• Systemic
  • Oral
  • Intravenous
  • Others

By Target:

• Tumour Necrosis Factor (TNF)
• Phosphodiesterase Type 4 (PDE4)
• Interleukin

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

In 2022, MEA accounted for a moderate share in the worldwide market. However, growing favorable efforts from the governments and rising improvements in healthcare infrastructure are expected to change the scenario and accelerate the growth momentum of this regional market. Due to the high prevalence of psoriasis throughout the Middle East and Africa, the UAE occupied the leading share in the MEA market in 2020.

KEY MARKET PLAYERS:

Companies playing an active role in the MEA Psoriasis Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck, and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).